ASTRAZENECA PHARMA INDIA
|
|
BOM : 506820     NSE : ASTRAZEN     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : None or < 25% |
Oct 11,2024 |
Price(EOD): ₹ 7,788.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 19,470.50 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ASTRAZENECA PHARMA INDIA | -0.6% | 12.8% | 66% |
SUN PHARMACEUTICAL INDUSTRIES | -0.2% | 3% | 68% |
CIPLA | -1.8% | -2% | 39.6% |
DR REDDYS LABORATORIES | -0.1% | -0.2% | 19.8% |
ZYDUS LIFESCIENCES | 1.4% | -4.2% | 76% |
DIVIS LABORATORIES | 13.7% | 12.9% | 60.4% |
FUNDAMENTAL ANALYSIS OF ASTRAZENECA PHARMA INDIA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ASTRAZENECA PHARMA INDIA
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
203.12
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 95.86 Cr
[Latest Qtr - Jun2024 - Standalone Results ] 27.48
P/B Calculated based on Book Value of Rs 708.63 Cr
[Latest Year - Mar2024 - Standalone Results ] 14.03
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Jun2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
116% 106% 114% |
SHARE PRICE MOMENTUM OF ASTRAZENECA PHARMA INDIA
ASTRAZENECA PHARMA INDIA vs SENSEX
DEBT OF ASTRAZENECA PHARMA INDIA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ASTRAZENECA PHARMA INDIA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ASTRAZENECA PHARMA INDIA
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
1.13% -22.92% -127.89% -129.87% |
31.15% -43.38% -121.23% -121.89% |
QtrlyTrend |
-4 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
ASTRAZENECA PHARMA INDIA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2% | 1.4% | 58.4% |
S&P BSE SMALL CAP | 1.2% | 0.2% | 49.5% |
S&P BSE MIDSMALLCAP | 1.1% | -0.1% | 50.3% |
S&P BSE 250 SMALLCAP | 1.1% | -0.6% | 45.8% |
S&P BSE 400 MIDSMALLCAP | 1% | -0.3% | 48% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MID SMALL400 | 1.2% | 0% | 46.6% |
NIFTY SMALLCAP250 | 1.1% | -0.9% | 47.9% |
NIFTY500 MULTICAP 50:25:25 | 0.6% | -0.2% | 39.9% |
NIFTY 500 | 0.3% | -0.1% | 36.5% |
You may also like the below Video Courses
FAQ about ASTRAZENECA PHARMA INDIA
Is ASTRAZENECA PHARMA INDIA good for long term investment?
As on Oct 11,2024, the Fundamentals of ASTRAZENECA PHARMA INDIA look Strong and hence it may be good for long term investment! See Financial Performance of ASTRAZENECA PHARMA INDIA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ASTRAZENECA PHARMA INDIA UnderValued or OverValued?
As on Oct 11,2024, ASTRAZENECA PHARMA INDIA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ASTRAZENECA PHARMA INDIA ?
As on Oct 11,2024, the Intrinsic Value of ASTRAZENECA PHARMA INDIA is Rs. 3,645.67 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3,601.44
Fair Value [Median EV / Sales Model] : Rs. 3,787.82
Fair Value [Median Price / Sales Model] : Rs. 3,645.67
Estimated Median Fair Value of ASTRAZENECA PHARMA INDIA : Rs. 3,645.67
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.